Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

Co-survival of the fittest few: Mosaic amplification of receptor
tyrosine kinases in glioblastoma
Chen Feng
Washington University School of Medicine in St. Louis

Li Ding
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Feng, Chen and Ding, Li, ,"Co-survival of the fittest few: Mosaic amplification of receptor tyrosine kinases
in glioblastoma." Genome Biology. 13,. 141. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/717

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Chen and Ding Genome Biology 2012, 13:141
http://genomebiology.com/2012/13/1/141

RESEARCH HIGHLIGHT

Co-survival of the fittest few: mosaic amplification
of receptor tyrosine kinases in glioblastoma
Feng Chen1 and Li Ding2,3*

Abstract
Mosaic amplification of receptor tyrosine kinases in
glioblastoma suggests that tumor cells with different
progression driver mutations may coevolve rather than
compete during clonal evolution.
Keywords Clonal evolution, tumor heterogeneity,
glioblastoma, mosaic amplification, receptor tyrosine
kinases, progression driver mutations

Heterogeneity, long recognized as a hallmark for cancers,
provides the platform for clonal evolution to occur. The
advancement of genome biology, especially next genera
tion DNA sequencing technology, has started to reveal
tumor heterogeneity at the gene level and, increasingly,
the nucleotide level. Deep sequencing of cancer genomes
in combination with sophisticated clustering algorithms
is being used to identify subclones with similar genomic
variant profiles with increasing confidence and resolu
tion. Comparisons of primary tumor samples with matched
metastatic samples, xenografts and relapse samples have
provided clues for delineating subclonal phylogenetic
evolutionary history, rooted at the primary tumor and
diverging into its various derivatives [1-7]. Ideally, such
studies would use single cell sequencing, which provides
the most detailed picture of tumor heterogeneity and
clonal evolutionary history. Indeed, this challenging
technique has recently been successfully used to infer the
evolutionary history of breast cancer cells based on copy
number variations [8]. However, the low genome
coverage and the intrinsic error rate in current DNA
sequencing technology limit the resolution with which
genomic variants are detected in these samples. A recent
study by Snuderl et al. [9] has revealed the mosaic ampli
fication of multiple receptor tyrosine kinases (RTKs) in
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glioblastoma multiforme (GBM) (Figure 1) and achieved
single-cell resolution, with regard to the selected target
genes, in dissecting tumor heterogeneity. The discovery
of mosaic amplification of RTKs in GBMs has broad
implications for tumor clonal evolution, the concept of
driver mutations, and treatment choices.

Mosaic amplification of receptor tyrosine kinases
in glioblastoma
Amplification of RTK genes, including those encoding
the epidermal growth factor receptor (EGFR), the vas
cular endothelial growth factor receptor (VEGFR2), the
platelet-derived growth factor receptor A (PDGFRA),
and the oncogenes KIT and MET, drives the tumori
genesis of GBM through the activation of the mitogenactivated protein kinase pathway. Usually, only one RTK
shows high-level amplification in a given GBM sample.
By analyzing The Cancer Genome Atlas (TCGA) project
copy number data, Snuderl et al. [9] found, unexpectedly,
that 6.3% (13 out of 206) of the GBM cases showed simul
taneous amplification of multiple RTKs. The authors
were able to confirm the coamplification of MET and
PDGFRA within the same tumor cells from a single
original TCGA case by fluorescent in situ hybridization
(FISH). Snuderl et al. [9] further studied their own GBM
cohort using FISH to detect gene amplification and
immunofluorescent staining to detect increased protein
production. They found that 4.5% (16 out of 350) of
GBMs have more than one amplified RTK. A genomewide copy number assessment, by array comparative
genomic hybridization, showed that the amplicons were
local, excluding the probability of coamplification due to
unusually high chromosomal instability. Unlike the single
TCGA case, these multiple RTK amplifications were
present in intermingled subpopulations of tumor cells
that are all mitotically active.
Nonlinear coevolution of tumor subclones
Snuderl et al. [9] found that in all cases with observed co
amplifications of RTKs, the CDKN2A and TP53 geno
types were concordant in each of the subpopulations,
suggesting that these subpopulations share the same
precursor and can be considered subclones within each
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Figure 1. A nonlinear clonal evolution model derived from the observation of mosaic amplification of receptor tyrosine kinases (RTKs) in
glioblastoma multiforme (GBM). The primary tumor and all of its derivatives carry the early driver mutation that initiates tumorigenesis. Multiple
progression driver mutations can occur in a non-linear manner, creating subpopulations with variable levels of fitness. Many times, a dominant
clone emerges before another round of diversification and selection pushes the clonal evolution forward. However, as illustrated by the coexistence
of subclones with amplification of different RTKs in some GBMs, subclones may coexist because of either similar fitness levels or a cooperative
relationship for enhanced tumor growth potential. Individual subclones and different combinations of them may occupy specific niches within the
tumor microenvironment. Relevant genes and niches from the Snuderl et al. study [9] are indicated in parentheses.

tumor. Not surprisingly, the ratios of subclones with
different amplified RTKs varied broadly among tumor
samples. A particularly intriguing finding is the spatial
distribution of the mosaic subclones within a complete
GBM brain autopsy. Although the EGFR- and PDGFRAamplified subclones are present at a 60:40 ratio in the
main tumor mass, the portion infiltrating other tissues
contained exclusively EGFR-amplified cells. The uneven
distribution suggests that each population may occupy a
distinct niche within the tumor microenvironment
(Figure 1). Furthermore, the coexistence of two subpopu
lations with different RTK amplifications could mean a

similar level of fitness for each of the subclones. It is even
possible that these subclones may cooperate to achieve
higher fitness than each of the subclones alone. This
scenario is very different from a linear clonal evolution
model in which subclones from the primary clone
compete for dominance and further mutations in the
dominant subclone initiate another round of selection.
The hypothesized cooperation among the subclones
warrants the survival of the fittest few. In fact, co
operation among different subpopulations of tumor cells
is not unprecedented. In GBM tumors with both
amplified wild-type EGFR (wtEGFR) and an activated
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form of this RTK (∆EGFR), the former is typically ex
pressed at far greater abundance. Inda et al. [10] showed
that cells with ∆EGFR secrete interleukin-6 and/or
leukemia inhibitory factor, both of which activate the
wtEGFR in neighboring cells through the receptor gp130,
enhancing the rate of tumor growth. Thus, cooperation
of tumor subclones can be achieved by paracrine signal
ing and can actively maintain tumor heterogeneity.
Although other tumor types may conceivably have
similar paracrine signaling among tumor subclones,
direct evidence is still lacking. The scarcity of fibroblasts
in GBMs may be a selection force for subclones that can
provide mitogenic signals and other forms of support for
tumor growth that are delivered by the stroma in other
tumors.

Multiplicity of drivers and therapeutic implications
By using a clever combination of genomic data, FISH,
immunofluorescent staining and other approaches,
Snuderl et al. [9] have revealed the mosaic amplification
of multiple RTKs in GBMs and delineated clonal
evolution within these tumors in molecular and spatial
detail. Clonal evolution is generally thought to be driven
by the driver mutations that provide a selective growth
advantage. Observations made in this study [9] highlight
the division of driver mutations into early (initiating)
drivers and late (progression) drivers. The tumor-initiat
ing driver, apparently the loss of CDKN2A in the GBMs
investigated in this study, is expected to be present in all
tumor cells. The late (or progression) drivers, such as
EGFR, PDGFRA and MET in this study, can be hetero
geneous within a single tumor.
The authors [9] also identified a case of salivary duct
carcinoma with amplification of ERBB2 and PDGFRA in
separate subclones, suggesting that the mosaic
amplification of multiple RTKs is not limited to GBMs.
The coamplification of multiple RTKs in GBMs and other
tumors may demand treatments targeting multiple RTKs.
However, if subclones with amplification of different
RTKs depend on each other for survival and growth,
hitting one partner may be sufficient to disrupt tumor
growth. A better understanding of the complex relation
ships among tumor subclones with amplifications of
different RTKs and other key genetic alterations would
guide the selection of the weakest link to target, thus
achieving the maximal therapeutic benefits with the
fewest side effects.
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